<< Return to
February 19 2009
's Biolgoics License Application (BLS) for
, an investigation drug seeking indication for the treatment and prevention of postmenopausal osteoporosis in women and treatment and prevention of bone loss in patients undergoing hormone ablation therapy for either prostate or breast cancer. Last July, IMS Health said denosumab had blockbuster potential, and could net sales over $1 billion.